Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2019-12-13 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform that an interaction with analysts / investors is scheduled to ....
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Ltd. addressed to stock exchanges (BSE and NSE) informing them about a scheduled interaction with analysts and investors. It references compliance with SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of a meeting schedule rather than a financial report, earnings release, or detailed presentation. The document length is short (1924 characters), and it does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Ltd. addressed to stock exchanges (BSE and NSE) informing them about a scheduled interaction with analysts and investors. It references compliance with SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, and provides details of the meeting date and location. The document is short (1924 characters) and serves as an announcement of an upcoming event rather than a financial report or detailed presentation. There is no financial data, no report attached or referenced as published, and no detailed management discussion or earnings information. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-13 English
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that a one-on-one meeting is scheduled to be held with following ....
Regulatory Filings Classification · 95% confidence The document is a letter dated December 4, 2019, addressed to stock exchanges (BSE Limited and National Stock Exchange of India Ltd.) regarding the schedule of interaction with analysts. It mentions a one-on-one meeting with analysts/investment managers. The content is an announcement of an upcoming event (analyst interaction) and does not contain financial statements, detailed financial data, or report content. The document length is short (2015 characters) and it serves as an intimation or notice rather than a full report or transcript. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-12-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter dated December 4, 2019, addressed to stock exchanges (BSE Limited and National Stock Exchange of India Ltd.) regarding the schedule of interaction with analysts. It mentions a one-on-one meeting with analysts/investment managers. The content is an announcement of an upcoming event related to investor relations, specifically a meeting with analysts. There is no financial data, no report attached or referenced as being published, and no detailed financial or management discussion. The document is short (2015 characters) and serves as a notification of an analyst interaction schedule. This fits best under Investor Presentation (IP) as it relates to investor communications and presentations, although it is more of a meeting schedule notice. However, since it is about interaction with analysts and investors, IP is the closest category. Confidence is high given the clear context and content.
2019-12-04 English
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. The document is an official notification related to share certificates, which fits the category of Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like share issue or director dealings. The document length is short and it is not a report or announcement of a report publication.
2019-12-04 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended September 30, 2019, pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed financial data on transactions with related parties, including purchases, sales, reimbursements, and balances receivable and payable. The document is 5701 characters long, which is sufficient to contain substantive financial data. This type of disclosure is typically part of regulatory compliance filings but is not a full financial report like an Annual Report or Interim Report. It is a specific regulatory disclosure related to related party transactions, which falls under the category of Regulatory Filings (RNS) as it does not fit into other specific categories such as Annual Report, Interim Report, or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-11-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.